From the Journals

Breast cancer care delayed when patients have high deductibles


 

FROM JOURNAL OF CLINICAL ONCOLOGY


The investigators conducted a controlled pre-post study to measure the occurrence of outcomes both before and after women were switched from a low-deductible health plan, defined as a maximum annual deductible of $500 or less, to a high-deductible plan, defined as an annual deductible of $1,000 or more.

The study population comprised 273,499 women aged 25-64 years who had no evidence of breast cancer before they were included in the study. The women had all been enrolled in a low-deductible plan for at least 1 year, and were then switched by employer mandate to a high-deductible plan and followed for up to 4 additional years.

Controls included 2.4 million women matched by time of inclusion whose employers continued to offer only low-deductible health plans.

Although at baseline there were no differences between the study sample and the controls in time to first diagnostic breast imaging, breast biopsy, diagnosis of early stage breast cancer, or initiation of breast cancer chemotherapy, at follow-up the women who had been switched to the high-deductible plans had significant delays in all categories.

Recommended Reading

Hodgkin lymphoma survivors are at an increased risk of subsequent ER-negative breast cancer
MDedge Hematology and Oncology
AHA: Heart health helps optimize breast cancer outcomes
MDedge Hematology and Oncology
PAM50-based score identifies low-risk subset with node-positive early-stage breast cancer
MDedge Hematology and Oncology
Cyclophosphamide extends PFS in elderly HER2+ breast cancer patients
MDedge Hematology and Oncology
Exercise during chemotherapy may yield long-term physical benefits
MDedge Hematology and Oncology
Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer
MDedge Hematology and Oncology
Measurement of physical activity and sedentary behavior in breast cancer survivors
MDedge Hematology and Oncology
Breast cancer deaths projected for 2018
MDedge Hematology and Oncology
FDA approves abemaciclib plus aromatase inhibitor as initial therapy
MDedge Hematology and Oncology
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Hematology and Oncology